Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Do you often replay the bad yet always forget the good? Here’s the science behind negative thought spirals and how to find balance and resilience. Do you know why our brains can replay our most ...

The S&P 500 was rising modestly Friday afternoon, adding to its October gains despite the U.S. government shutdown this month. The S&P 500 was up 0.3% in afternoon trading after returning to positive ...

Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...

Former Vice President Kamala Harris offered up several criticisms of the Biden White House’s communications team in her new book, painting a picture of a staff that did little to defend her. "They had ...

Giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer, marking a milestone in SERD regimen trials. The trial met co-primary endpoints, benefiting patients ...

Asking for forgiveness may be mandated by our tradition at this time of year, and if we do it right, it’s one of the toughest things we’re called to do. Who wants to be reminded that they messed up, ...

Mahomes has already put up some Hall of Fame credentials. Amazingly, he’s still got a way to go if he wants to catch the G.O.A.T. Craig Ellenport is a senior editor at Athlon Sports. A veteran sports ...

Former Vice President Kamala Harris accused staffers of former President Biden of “adding fuel” to negative stories about her during their time in office in an excerpt published Wednesday from her ...

Background: The present study aimed to evaluate the cost-effectiveness of pembrolizumab combined with chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally ...